USCAP 2024: Routine use of an artificial intelligence solution for primary diagnosis of prostate biopsies in clinical practice

Back

In a study conducted at UPMC, researchers assessed Galen Prostate’s performance in primary diagnosis of prostate biopsies, employed in a digital pathology workflow. The study found the AI-powered solution was highly accurate in identifying and grading cancer in a live clinical setting. The study also demonstrated positive feedback from participating pathologists, showing high satisfaction, particularly with Galen Prostate’s Gleason scoring, detection of perineural invasion and automated measurement of tissue and tumor length.

Back

About IBEX

IBEX is the leader in AI-powered cancer diagnostics in pathology. We empower physicians to provide every patient with an accurate, timely and personalized cancer diagnosis. Our AI platform is deployed worldwide, supporting pathologists and providers with AI-insights that help improve the quality and accuracy of diagnosis, reduce turnaround times and boost productivity.

By providing my details I agree to the IBEX-AI Terms and conditions and Privacy policy. I also agree to receive emails form IBEX-AI and I understand that I may opt out of IBEX-AI subscriptions at any time.

About IBEX

IBEX is the leader in AI-powered cancer diagnostics in pathology. We empower physicians to provide every patient with an accurate, timely and personalized cancer diagnosis. Our AI platform is deployed worldwide, supporting pathologists and providers with AI-insights that help improve the quality and accuracy of diagnosis, reduce turnaround times and boost productivity.

By providing my details I agree to the IBEX-AI Terms and conditions and Privacy policy. I also agree to receive emails form IBEX-AI and I understand that I may opt out of IBEX-AI subscriptions at any time.

How is artificial intelligence rising to the challenge in breast cancer diagnosis?

How ‘game-changing’ AI is helping discover cancer for the first time in UK | ITV News

The AI revolution in cancer diagnostics with Joseph Mossel, CEO of Ibex Medical Analytics